Journal of Diabetes and Its Complications · Nov 2026

Beyond weight loss: GLP-1–based therapies and the reversal of type 2 diabetes pathophysiology

By Rossatto T, de Andrade Oliveira R, Manica A et al.

Glucagon-like peptide-1 (GLP-1)-based therapies have transformed the treatment of type 2 diabetes (T2D), producing substantial improvements in glycemic control and, with newer agents, unprecedented reductions in body weight. However, their effects extend beyond these conventional outcomes and include reductions in visceral and hepatic fat, improved insulin sensitivity, attenuation of glucolipotoxicity, and enhancement of β-cell function. These actions overlap with mechanisms implicated in the reversal of T2D following substantial weight loss, raising the possibility that GLP-1-based therapies may modify the underlying pathophysiology of the disease rather than simply control its metabolic manifestations. In this review, we integrate evidence linking ectopic fat accumulation, hepatic insulin resistance, altered lipid trafficking, oxidative and inflammatory stress, and β-cell dysfunction with the development and reversibility of T2D. We then examine how GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism remodel these metabolic and cellular abnormalities and discuss whether such changes may facilitate β-cell functional recovery. Particular attention is given to the distinction between treatment-induced normoglycemia and medication-free remission. Although current evidence indicates that GLP-1-based therapies can profoundly modify the diabetic metabolic phenotype, durability after treatment withdrawal remains uncertain. We propose that the potential for disease modification may depend on the interaction between the magnitude of metabolic unloading and residual β-cell functional reserve. Prospective withdrawal studies incorporating detailed assessments of β-cell function, insulin sensitivity, and ectopic adiposity are needed to determine whether early and profound incretin-based intervention can translate metabolic normalization into durable, medication-independent remission of T2D.

doi.org/10.1016/j.jdiacomp.2026.109453Interventions

AgingResearch.News